Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2018

Open Access 01.12.2018 | Correspondence

Oral anticoagulation in high risk Takotsubo syndrome: when should it be considered and when not?

verfasst von: Francesco Santoro, Thomas Stiermaier, Francesca Guastafierro, Nicola Tarantino, Ingo Eitel, Natale Daniele Brunetti

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2018

Abstract

Standard pharmacological therapy in Takotsubo syndrome (TTS) is still debated and there is a lack of prospective data. In their recent work in BMC Cardiovascular Disorders Abanador-Kamper et al. found that stroke in TTS has an event rate of 2.8% after 30 days and 4.2% after 12 months and they question which patients need oral anticoagulation. According to our clinical data, TTS patients with LV thrombi may be at high risk of stroke. These patients are characterized by apical ballooning pattern, high prevalence of ST-elevation and higher troponin I levels. We have recently proposed a therapeutic algorithm for oral anticoagulation in TTS. In case of apical ballooning pattern and increased admission levels of troponin-I (> 10 ng/mL), oral anticoagulation should be considered, while in case of midventricular/basal ballooning or apical ballooning associated with troponin-I levels < 10 ng/ml, oral anticoagulation should not be considered. A simple combination of echocardiographic parameters (apical ballooning pattern),ECG data (ST-elevation at admission and persistent after 72 h) and laboratory values (troponin serum levels) could be useful for an appropriate therapeutic management of oral anticoagulation in TTS.
We read with great interest the article from Abanador-Kamper et al. entitled “Temporarily increased stroke rate after Takotsubo syndrome: need for an anticoagulation?” [1]. In this study 72 patients with Takotsubo Syndrome (TTS) were enrolled and all were evaluated by cardiac magnetic resonance imaging during the acute phase and 2 months later. The stroke rate was 2.8% after 30 days and 4.2% after 12 months. Patients with stroke presented with apical ballooning and no one of them received prior anticoagulation.
Left ventricular (LV) thrombus formation was found in one patient (1.3%) with acute stroke. However, the real rate of LV thrombi may have been underestimated because thrombus formation can happen even 2 weeks after the acute event [2]. Stroke could also be a trigger for TTS due to the dysfunction of central autonomic network associated with cerebral infarction, especially involving the territory of middle cerebral artery or basilar artery [3]. Unfortunately, Abanador-Kamper et al. did not provide additional information regarding serum levels of troponin and ECG data.
In a multicenter study enrolling 541 TTS patients we found that 12 patients (2.2%) developed LV thrombi (all female presenting with apical ballooning pattern) [4]. Among these patients, 2 out of 12 (17%) had a stroke before anticoagulation initiation. These patients were characterized by a high prevalence of ST-elevation and higher troponin I levels. Troponin I levels > 10 ng/mL were the only predictor of LV thrombosis (normal values = 0.5 ng/ml).
According to this data we proposed a therapeutic algorithm for oral anticoagulation (Fig. 1). In case of an apical ballooning pattern and increased admission levels of troponin-I (> 10 ng/mL), oral anticoagulation should be considered, while in case of mid-ventricular/basal ballooning or apical ballooning associated with troponin-I levels < 10 ng/ml, oral anticoagulation should not be considered. Moreover, we also found that the presence of persistent ST-elevation during the first 72 h after admission is associated with LV thrombosis [5].
A simple combination of echocardiographic parameters (apical ballooning pattern), ECG data (ST-elevation at admission and persistence after 72 h) and laboratory values (troponin serum levels) could be useful for an appropriate therapeutic management of oral anticoagulation in TTS.
The high rates of stroke during the first 30 day after TTS remarks the urgent need of randomized trials assessing the role of anticoagulation in TTS.

Response to “Oral anticoagulation in high risk Takotsubo syndrome: When should it be considered and when not?”

Nadine Abanador-Kamper3, 4  , Lars Kamper3, 4, Judith Wolfertz3, 4, Marc Vorpahl3, 4, Patrick Haage5 and Melchior Seyfarth3, 4
(3)
Department of Cardiology, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany
(4)
Center for Clinical Medicine Witten/Herdecke University Faculty of Health, Wuppertal, Germany
(5)
Department of Diagnostic and Interventional Radiology, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany
 
 
Nadine Abanador-Kamper
We thank the authors for this important contribution and agree that prospective RCTs are urgently needed to define a therapeutic algorithm in patients with TTS and the need for anticoagulation.
Not applicable
Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Abanador-Kamper N, Kamper L, Wolfertz J, Vorpahl M, Haage P, Seyfarth M. Temporarily increased stroke rate after Takotsubo syndrome: need for an anticoagulation? BMC Cardiovasc Disord. 2018;18:117.CrossRef Abanador-Kamper N, Kamper L, Wolfertz J, Vorpahl M, Haage P, Seyfarth M. Temporarily increased stroke rate after Takotsubo syndrome: need for an anticoagulation? BMC Cardiovasc Disord. 2018;18:117.CrossRef
2.
Zurück zum Zitat Singh V, Mayer T, Salanitri J, Salinger MH. Cardiac MRI documented left ventricular thrombus complicating acute Takotsubo syndrome: an uncommon dilemma. Int J Cardiovasc Imaging. 2007;23:591–59.CrossRef Singh V, Mayer T, Salanitri J, Salinger MH. Cardiac MRI documented left ventricular thrombus complicating acute Takotsubo syndrome: an uncommon dilemma. Int J Cardiovasc Imaging. 2007;23:591–59.CrossRef
3.
Zurück zum Zitat Santoro F, Carapelle E, Cieza Ortiz SI, Musaico F, Ferraretti A, d'Orsi G, Specchio LM, Di Biase M, Brunetti ND. Potential links between neurological disease and Tako-Tsubo cardiomyopathy: a literature review. Int J Cardiol. 2013;168(2):688–91.CrossRef Santoro F, Carapelle E, Cieza Ortiz SI, Musaico F, Ferraretti A, d'Orsi G, Specchio LM, Di Biase M, Brunetti ND. Potential links between neurological disease and Tako-Tsubo cardiomyopathy: a literature review. Int J Cardiol. 2013;168(2):688–91.CrossRef
4.
Zurück zum Zitat Santoro F, Stiermaier T, Tarantino N, L. De Gennaro C. Moeller F. Guastafierro M.F. Marchetti R. Montisci T. Graft P. Caldarola H. Thiele M. Di Biase N.D. Brunetti I. Eitel. Left ventricular thrombi in Takotsubo syndrome: incidence, predictors and management. Results from the German Italian stress cardiomyopathy (GEIST) registry. J Am Heart Assoc. 2017;6(12). https://doi.org/10.1161/JAHA.117.006990. Santoro F, Stiermaier T, Tarantino N, L. De Gennaro C. Moeller F. Guastafierro M.F. Marchetti R. Montisci T. Graft P. Caldarola H. Thiele M. Di Biase N.D. Brunetti I. Eitel. Left ventricular thrombi in Takotsubo syndrome: incidence, predictors and management. Results from the German Italian stress cardiomyopathy (GEIST) registry. J Am Heart Assoc. 2017;6(12). https://​doi.​org/​10.​1161/​JAHA.​117.​006990.
5.
Zurück zum Zitat Santoro F, Stiermaier T, Tarantino N, Guastafierro F, Graf T, Moller C, Di Martino LFM, Thiele H, Di Biase M, Eitel I, Brunetti ND. Impact of persistent ST elevation on outcome in patients with Takotsubo syndrome. Results from the GErman Italian STress cardiomyopathy (GEIST) registry. Int J Cardiol. 2018;255:140–4.CrossRef Santoro F, Stiermaier T, Tarantino N, Guastafierro F, Graf T, Moller C, Di Martino LFM, Thiele H, Di Biase M, Eitel I, Brunetti ND. Impact of persistent ST elevation on outcome in patients with Takotsubo syndrome. Results from the GErman Italian STress cardiomyopathy (GEIST) registry. Int J Cardiol. 2018;255:140–4.CrossRef
Metadaten
Titel
Oral anticoagulation in high risk Takotsubo syndrome: when should it be considered and when not?
verfasst von
Francesco Santoro
Thomas Stiermaier
Francesca Guastafierro
Nicola Tarantino
Ingo Eitel
Natale Daniele Brunetti
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2018
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0930-1

Weitere Artikel der Ausgabe 1/2018

BMC Cardiovascular Disorders 1/2018 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.